According to Ernst & Young’s June report, 2011 revenues for public biotech firms in the US, Europe, Canada and Australia grew 10% on a normalized basis to $83.4 billion and R&D expenses rose 9% to $23.1 billion. US sales rose 12% to $58.8 billion on a normalized basis, with R&D spending up 9% to $17.2 […]

In its June World Preview 2018, EvaluatePharma forecasts the compound annual growth rate (CAGR) of global R&D spending by drug firms to reach $149 billion. R&D spending 2004–2010 grew at a CAGR of 6.5% to $128 billion. Year over year, the rate of R&D spending is expected to drop 0.3% in 2012 to $134 billion […]

Conducted in February, KPMG’s Global Manufacturing Outlook survey questioned 241 executives from the aerospace and defense, metals, engineering and industrial products sectors, conglomerates. All questions concerned the time period of the next one to two years. Seventy-five percent of respondents have a positive outlook. When asked what factors would be most vital to profits, 65% […]

Prompted by a mandatory five-year review of particle pollution standards under the Clean Air Act, the EPA proposed an update to the National Ambient Air Quality Standards to lower the limit for fine particle pollution from 15 µg/m3 to 12–13 µg/m3. The EPA also proposed an alternate limit of 11 µg/m3. The proposal stipulates that […]

Regulatory issues are the top concern and the factor that will most affect capital-spending decisions this year for 47% and 46%, respectively, of the 225 financial executives from energy firms who responded to KPMG’s global 2012 energy survey in April. For 2012, 60% of executives expect their firms’ capital spending to increase, with 26% predicting […]